



A post glucose challenge state of glucose tolerance, 
intermediate	between	that	defined	as	normal	and	that	classified	
as diabetes, was described in 1979 and in 1980, respectively, 
by	 both	 the	American	National	Diabetes	Working	Group	
and	 the	World	Health	Organization	 (WHO)	 to	 replace	 the	
terms – borderline, chemical, and asymptomatic diabetes 
mellitus.[1] This apparently new state, which was termed 
impaired	glucose	tolerance	(IGT)	or	prediabetes,	represented	
a raised 2 hours plasma glucose level of between 140 and 
199 mg/dL (7.8–11.0 mmol/L) in an individual who had normal 
fasting plasma glucose levels.[1] In addition, individuals in this 
new category were discovered to have an increased tendency 
towards developing type 2 diabetes mellitus (T2DM) in future 
and cardiovascular disease.
Close	to	two	decades	after	the	term	IGT	was	adopted,	a	different	
but related category of elevated, nondiabetic range of fasting 
plasma glucose levels which also predicted future diabetes 
was likewise-reported in some individuals. This was termed 
impaired	 fasting	 glucose	 (IFG)	 by	 the	American	Diabetes	
Association (ADA) in 1997 and was subsequently adopted 
by	the	WHO	in	1999,	as	impaired	fasting	glycemia	(IFG).[1] 
Thus,	IFG	was	defined	as	a	fasting	plasma	glucose	value	of	
110–125 mg/dL (6.1–6.9 mmol/L).[2]
However,	 over	 time,	 several	 research‑based	 data	 evidence	
showed	 that	 the	 lower	 limit	 of	 110	mg/dL	 for	 IFG	was	
unconvincing, as it was found to be the exact threshold 
predictive of future diabetes, in an individual. The sore point 
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over the years, had been the resetting of the fasting cutoff 
point for making a diagnosis of diabetes from 140 mg/dL 
to 126 mg/dL (i.e from 7.8 mmol/L to 7.0 mmol/L) which 
was	done	at	the	exact	time	that	IFG	was	officially	adopted.	
This resetting thereby effectively removed the group with 
the	highest	risk	for	the	progression	to	diabetes	from	the	IFG	
population and subsequently rendered it less predictive of 
future	diabetes	when	compared	to	IGT.[1]
In view of the above apparent shortcomings, the ADA in 2002, 
through	its	expert	committee	on	the	diagnosis	and	classification	
of diabetes,[3]	 lowered	 the	 cutoff	 point	 for	 IFG,	 citing	data	
from several longitudinal studies to support their action. 
Hence,	100	mg/dL	(5.6	mmol/L)	was	chosen	by	the	ADA	as	
the lower cutoff point for predicting future diabetes using the 
IFG,[3]	while	the	WHO	retained	the	initial	lower	cutoff	point	
for fasting plasma glucose value at 110 mg/dL (6.1 mmol/L).[2]
Glycosylated	hemoglobin	(HbA1c)	values	between	5.6	and	6.4%	
have	also	been	defined	as	prediabetes.[4]	However,	the	HbA1c	
is only recommended as an additional diagnostic criterion, not 
a primary one, as results may be misleading in several ethnic 
populations	due	to	some	innate	ethno‑specific,	metabolic,	and	
environmental factors including hemoglobinopathies – with 
resultant high red blood cell turnover and chronic iron 
deficiency	anemia.[5,6]
Currently, 352 million people worldwide (7.3% of adults 
20–79	years)	are	estimated	to	have	IGT	alone	(one	component	
of prediabetes) and 72.3% of them reside in low and middle 
income countries. This number is projected to increase to 587 
million (8.3% of adults 20–79 years) by 2045.[7] Equally of 
note	is	that	nearly	one‑third	of	adults	with	IGT	belong	to	the	
age category 20–39 years and hence are likely to spend many 
years at high risk of developing T2DM and other associated 
health-care challenges.[7] Nigeria, a country in Sub-Saharan 
Africa, is currently among the top ten countries with the highest 
number	of	individuals	with	IGT	worldwide.	It	is	projected	that	
another Sub-Saharan African country; Ethiopia, located in East 
Africa will also join these top ten countries by the year 2045.[7]
The	IGT	and	IFG	are	clearly	 two	separate	metabolic	states	
with marked differences in their prevalence and population 
of people affected.[8] Most population studies record a higher 
prevalence	for	IGT	than	for	IFG,	with	the	former	being	more	
prevalent	among	females,	while	the	IFG	seems	to	have	a	bias	
for the male gender.[9]	In	addition,	IGT	has	also	been	noted	




their abnormal glycemic state, with possible progression in the 
distant future, and an annual progression rate estimated to be 
between 10 and 12%.[10,11] The remaining quarter will revert to 
normal	glucose	tolerance	(NGT)	over	a	period	of	3–5	years.[10,11]
Some races, including the Afro-Caribbean, Asian, and 
Hispanics,	for	some	unclear	reasons,	tend	to	have	a	high	risk	
for developing prediabetes.[12] Interestingly, these races are 
clustered in the low and middle income countries which also 
have the highest prevalence of T2DM.[7] In addition, recent 
studies have observed a shift from the traditional lower 
prevalence rates of diabetes in rural African communities 
towards higher urban values, possibly due to the increasing 
adoption of “westernized” cultures.[13]
MoRbIdIty and MoRtalIty of PRedIabetes
Individuals with prediabetes tend to have similar vascular risk 
factors (dyslipidemia, hypertension, insulin resistance (IR), 
physical inactivity, obesity, endothelial dysfunction, 
pro‑coagulant	state,	and	inflammation)	that	put	patients	with	
T2DM at heightened risk of macrovascular complications.[14]
A	significant	number	of	people	with	IGT	and	IFG	will	advance	
to diabetes within a few years if left untreated,[15] though there 
appears to be a stronger evidence for advancement in patients 
with	IGT	than	IFG.[16]
Evidence shows that prediabetes increases the tendency in 
individuals of developing heart diseases, eye diseases, kidney 
diseases and stroke,[14,17]	with	 IGT	 emerging	 as	 a	 stronger	
predictor	of	macrovascular	complications	than	IFG.[14]
With the exponential increase in the prevalence of prediabetes 
and in effect diabetes, a great surge in diabetes-related morbidity 
and mortality is envisaged, with adverse socioeconomic 
consequences.
PathogenesIs of PRedIabetes – the “Portentous 
Pentad”
Normal plasma glucose levels in the body are largely 
maintained	through	a	complex,	dynamic,	and	efficient	interplay	
between	plasma	glucose	 and	 insulin.	 Prediabetes	 has	 been	
described as a transitional, median phase over a sequence, 
extending	from	NGT	to	frank	T2DM.[15,18]
However,	of	the	eight	pathogenetic	pathways	(“ominous octet”)[19] 
for the development of T2DM (1. IR, 2. impaired insulin 
secretion, 3. increased lipolysis, 4. increased glucagon 
secretion,	5.	incretin	deficiency/resistance,	6.	increased	hepatic	
glucose production, 7. increased glucose reabsorption in the 
kidneys, and 8. decreased dopamine secretion in the brain. Only 
the	first	five	of	these,	which	collectively,	may	be	described	as	
the “portentous pentad” (1. IR, 2. impaired insulin secretion, 
3. increased lipolysis, 4. increased glucagon secretion, and 
5.	 incretin	deficiency/resistance)	 actually	play	 a	 role	 in	 the	
pathogenesis of prediabetes [Figure 1].[20]
IR and suboptimal glucose sensing at the beta cell, which 
results in impaired insulin secretion, are the two predominant 
pathophysiological determinants that together cause 
hyperglycemia.[14,15,21] Current evidence favors a two-step 
development,	whereby	 individuals	with	NGT	progress	 to	
prediabetes with IR as the primary determinant. Subsequently, 
there is a worsening of prediabetes to T2DM, driven by a 
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progressive deterioration in beta-cell function and insulin 
sensitivity.[16,21]
Insulin resistance
IR appears to be the outcome of a multiplex interplay between 
strong genetic predisposition and environmental factors including 
weight gain, physical inactivity, and aging.[16,18] In general, IR 
points to the presence of a reduced peripheral tissue response to 
endogenously secreted insulin. Characteristically, it presents as 
both reduced insulin-mediated glucose uptake, at the level of 
adipose and skeletal muscle tissue, and as impaired suppression 
of hepatic glucose output.[15] Insulin sensitivity, which is 
somewhat	the	opposite	of	IR,	is	a	measure	of	how	efficiently	a	
given unit of plasma insulin is able to lower the plasma glucose 
over a given period of time and can be assessed directly, using 
the hyperinsulinemic-euglycemic clamp.[22-24] Therefore, an 
individual who has a low insulin sensitivity, invariably, is said 
to have high IR. Since the exacting nature of the euglycemic 
clamp procedure, IR can be extrapolated clinically, using a 
surrogate measure, known as the homeostatic model assessment 
of	IR	(HOMA‑IR),	such	that	the	higher	the	HOMA‑IR	value,	
the higher the IR in the subject. This in effect translates to a 
higher propensity toward developing prediabetes and eventually 




Impaired insulin secretion/beta‑cell dysfunction
Although IR is a major pathogenic factor inducing progression 
from	NGT	to	IGT	to	T2DM,	deterioration	in	glycemic	control	
does not occur unless the beta-cells fail to compensate for 
the IR. Ultimately, beta-cell failure is responsible for the 
progression	of	IGT	to	T2DM.[16]
Among	IGT	patients,	a	low	2‑h	plasma	insulin	concentration	
during	an	oral	glucose	 tolerance	 test	 (OGTT)	predicts	 IGT	
progression to T2DM in all ethnic groups.[16] At fasting plasma 




An important characteristic of the beta-cell is its ability to 
upregulate insulin secretion in response to IR, and the extent to 
which the cells are able to perform this role is referred to as the 
disposition index (DI)[22-24]	and	is	represented	by	the	equation:
DI = Insulin sensitivity × Insulin secretion.
In effect, the DI mirrors the ability of the beta-cells of the 
pancreatic islets to compensate for IR, by increasing beta-cell 
responsiveness through increased insulin secretion. This 
increased responsiveness of the beta cells has been touted 
as possibly the most important factor in the maintenance of 
NGT	and	normal	fasting	glucose	and	in	the	early	stages	of	IR	
in	individuals.	However,	as	the	DI	decreases,	the	individual	
then tends toward prediabetes and eventually T2DM.[22-24] In 
a study on beta-cell responsiveness in Nigerian patients with 
Type 2 DM, the authors reported low fasting and postprandial 
beta-cell responsiveness in the patients, which was also 
strongly	correlated	with	 their	HBA1c	levels.	Their	findings	
suggest that beta-cell dysfunction occurs early in the natural 
history of the disease in these patients.[25]
Increased lipolysis
Adipocytes have been shown to play a part in the pathogenesis 
of T2DM through the action of some fat cells that develop 
abnormal metabolism and structure. The resultant alterations in 
the structure and internal cell functioning then cause these cells 
to become resistant to insulin’s antilipolytic effect, resulting in 
chronically elevated plasma free fatty acid concentration. This 
leads to the stimulation of gluconeogenesis and induction of 
liver and muscle cell IR with impairment of insulin secretion.[19] 
In addition, the high levels of disruptive “bad” adipocytokines 
produced by these aberrant fat cells, at the expense of the 
“good,” insulin-sensitizing adipocytokines like adiponectin, 
induce	inflammation,	atherosclerosis,	and	IR.	Indeed,	current	




been demonstrated to also play a part in glucose homeostasis 
and both have been shown to stimulate insulin secretion by the 
Figure 2: Prevalence of prediabetes in selected Sub‑Saharan African 
countries
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Figure 1: Pathophysiological defects in type 2 diabetes mellitus and 
prediabetes
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pancreatic beta cells in normal individuals.[19] Their secretion 
in the gut, however, only follows glucose ingestion (as against 
intravenous glucose administration) such that the higher the 
glucose level in the gut, the higher the incretin hormone secreted 
and vice versa. Individuals with prediabetes have reduced 
GLP‑1	 levels	plus	 a	 resistance	 to	 the	 stimulatory	 effects	of	
GIP	on	insulin	secretion.[19] In addition to the above-mentioned 
glucose‑dependent	insulin	secretion,	the	GLP‑1	also	strongly	
inhibits glucagon secretion, thereby suppressing hepatic glucose 
output and hence maintaining plasma glucose levels within 
the	normal	 range.	Conversely,	 incretin	deficiency/resistance	
naturally results in elevated plasma glucose levels.
Increased glucagon secretion
Abnormally high levels of glucagon, produced by the 
pancreatic alpha cells, have been observed in subjects with 
prediabetes, and this has been shown to be responsible for 
the increased rates of hepatic glucose output, with resultant 
hyperglycemia.[19]
Molecular/genomics aspects of the pathogenesis of 
prediabetes
The place of epigenetic mechanisms in the pathogenesis of 
prediabetes has been brought to the fore with recent data-based 
evidence of abnormal deoxyribonucleic acid (DNA) 
methylation in individuals with prediabetes and diabetes. In 
their preliminary genome-wide DNA methylation analysis in 
South Africa, Matsha et al.[27] reported hypomethylation of 
differentially methylated gene regions (DMRs) associated with 
the linoleic acid metabolism as well as the arachidonic acid 
metabolism pathways in subjects with prediabetes but not in 
normal controls. In these same individuals with prediabetes, 
hypermethylation of DMRs were observed in genes involved 
in the immune system, signal transduction, glucose transport 
and insulin signaling pathway as well as muscle and 
pancreas development. They have also been associated with 
inflammatory	pathways.	Therefore,	epigenetic	changes	were	
thought to be an early process that precedes the development of 
prediabetes and diabetes;[27] hence, further research may throw 
more light on the utility of these DMRs as possible biomarkers 
of disease onset or progression.
Recently, the role of secreted frizzled-related protein 
4	 (SFRP4)	 in	 the	 pathogenesis	 of	 prediabetes	 and	T2DM	
has been highlighted.[28]	The	SFRP4,	a	member	of	the	SFRP	
family that contains a cysteine-rich domain, homologous to the 
harmful “wingless/integrated” (Wnt) binding site of frizzled 
proteins, acts as soluble modulators of Wnt signaling. The Wnt 
signaling pathways are a group of signal transduction pathways 
that begin with proteins that pass signals into a cell through 
cell	surface	receptors.	The	SFRP4	gene	is	highly	expressed	in	
human islet cells, in addition to various other cells and levels 
which are found to be increased, several years before the onset 
of	diabetes.	Studies	have	shown	that	high	levels	of	SFRP4	are	
associated with IR, β‑cell	dysfunction,	IGT,	and	T2DM.[28]
Another relatively new molecule, which has been implicated 
in the pathogenesis of prediabetes and T2DM, is known as 
fractalkine	(FKN).	This	pro‑inflammatory	cytokine,	produced	
by nonhemopoietic cells, is the only known member of the 
CX3C	chemokine	family	and	has	a	G‑protein‑coupled	receptor	
known as CX3CR1.[29]	 FKN	 has	 been	 shown	 to	 promote	
chemotaxis	 and	 adhesion	 in	 the	 presence	 of	 inflammation	
and is thought to drive the migration of leukocytes to tissues 
during	 inflammatory	 processes.	Through	 this	mechanism,	
FKN	is	believed	to	mediate	the	adipose	tissue	inflammation	
associated with T2DM. The ensuing monocyte accumulation 
in the adipocytes then leads to abnormal structure and function 
of the fat cells which then starts to produce high levels of 
disruptive	adipocytokines,	resulting	in	systemic	inflammation	
and IR.[20,30]
Lee et al.,	 in	 their	 animal	 study,	 described	 the	FKN/FKN	
receptor axis – CX3CL1/CX3CR1 – and demonstrated that the 
axis functioned to promote increased insulin secretion, both 
in vitro and in vivo.	 In	addition,	while	CX3CR1	deficiency	




it enhanced glucose-stimulated insulin secretion with an 
associated reduction in β-cell apoptosis; enhanced hepatic 
insulin sensitivity, and reduced α-cell glucagon secretion.[31]
Among newly diagnosed T2DM patients versus those 
with	NGT,	Baldane	et al.	 found	 significantly	 higher	 basal	
OGTT	 (0‑min)	 and	 120‑min‑FKN	 levels	 in	 the	 newly	
diagnosed	T2DM	 group,	 compared	 to	 the	 NGT	 group.	
However,	 intra‑group	 FKN	values	 showed	 no	 significant	
change following a 75 g glucose load.[30]
RIsk factoRs foR PRedIabetes
The development of prediabetes is usually promoted by some 
major	risk	factors,	most	of	which	are	modifiable.	Landmark	
clinical research shows that intensive lifestyle changes mainly, 
in addition to early intervention with some pharmacological 
agents, have the potential to reverse prediabetes and even 
prevent or delay the development of T2DM.[32-38]
These risk factors include overweight/obesity, IR, physical 
inactivity, high blood pressure, dyslipidemia, age (45 years 
and	above),	family	history	of	diabetes	in	first‑degree	relatives,	
polycystic ovary syndrome, gestational diabetes, inadequate 
night sleep, and race.[8,12]	However,	in	a	recent	study	among	
a bi-racial cohort, Dagogo-Jack et al. revealed that people 
of African descent and Caucasians had an equal risk for the 
development of prediabetes.[39]
PRedIctoRs of PRedIabetes
Although independent risk factors for prediabetes have 
been defined, it does not follow automatically that every 
individual with either one or a combination of these risk 
factors	must	eventually	develop	prediabetes.	However,	some	
specific	pointers	have	been	shown	to	predict,	with	a	relatively	
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high level of certainty, the development of prediabetes 
in at-risk individuals.[18] These predictors of prediabetes 
include age >40 years, body mass index >30 kg/m2, waist 
circumference >92 cm, total fat mass >30 kg, trunk fat 
mass	>14.2	kg,	 2‑h	plasma	glucose	 (2‑HrPG)	>120	mg/dl,	
serum high density lipoprotein levels <48 mg/dl, and serum 
triglycerides >110 mg/dl. Other predictors of prediabetes also 
include decreased insulin sensitivity <1.2 µmol/kg FFM-min/
pM, a DI value <700, a low diet-adjusted physical activity level, 
a serum adiponectin level <9.5 µg/ml	in	women,	and	≤7.0	µg/ml 
in	men,	or	specifically	≤9.5	µg/ml	in	Caucasians	and	≤7.3	µg/ml 
in blacks.[18,39] Of these predictors, the combination of increased 
trunk	fat	and	2‑HrPG	≥90th percentile was found to confer a 
particularly high risk for the development of prediabetes[18] and 
hence can be deployed as an easy and affordable screening tool 
for prediabetes.
PRevalence of PRedIabetes – data fRoM 
sub‑sahaRan afRIca
Sub-Saharan Africa, most of whose countries belong to the low 
and middle income group of countries, is part of the region 
projected to record the fastest growth rate for prediabetes 
prevalence in the near future.[7] This unfortunate trend is 
superimposed on the already heavy burden of infectious 
diseases ravaging its people, thereby taking a heavy toll on the 
scant	human	and	financial	resources	available	to	the	region.	
The state of affairs regarding prediabetes prevalence in the 
different regions of Sub-Saharan Africa is outlined below 
and in Figure 2.
Prediabetes in east Africa
Studies on the prevalence of prediabetes in parts of East Africa 
have shown wide variations in prevalence with differing values 
among urban and rural areas as well as between males and 
females.
In Seychelles, a rapidly developing country in the East African 
region,	bordered	by	Kenya	and	Mauritius,	the	prevalence	of	IGT	
and	IFG	was	10.4%	and	24.2%,	respectively.[40] In rural Eastern 
Uganda, among persons aged 35–60 years, the prevalence 
of	 IFG	 alone	was	 8.6%	 (WHO	criteria)	 and	 20.2%	 (ADA	
criteria).[41]	Here,	obesity	emerged	as	the	most	significant	factor	
associated	with	 prediabetes.	However,	 a	more	 recent	 study	
revealed	the	prevalence	of	IFG	among	adults	in	rural	Uganda	as	
26.5% and 13.7% in peri-urban Uganda. In a cohort of teachers 
in	urban	Tanzania,	the	prevalence	of	IFG	was	as	low	as	2.4%.[42] 
Among urban and rural adults in Zimbabwe, prediabetes was 
prevalent at 5.3% and 5.2% in males and females, respectively, 
using	 the	WHO	criteria.[43]	 In	urban	Mozambique,	 IFG	was	
prevalent	at	2.3%	and	2.6%	(WHO	criteria)	among	adult	males	
and females, respectively.[42] Among a cross-section of all the 
inhabitants of urban Lusaka.[44] Among a cross-section of all the 
inhabitants	of	urban	Lusaka	Zambia,	IFG	was	prevalent	at	1.3%	
in both sexes.[45]	The	IGT	was	prevalent	at	6.1%	and	13.1%	




females had 11.9%.[47] Among a cross-section of both urban 
and	rural	Malawi	adults,	IFG	was	prevalent	at	5.7%	in	males	
and 2.7% in the females.[48] In a rural Ethiopian community, 
IFG	was	found	to	be	prevalent	in	12.0%	of	the	adult	population	
with	no	significant	gender	bias.[49]
Prediabetes in central Africa
In	rural	Angola,	the	prevalence	of	IGT	among	adult	males	was	
5.6%, while it was 9.1% in females.[50] Screening of a section 
of the inhabitants in the Democratic Republic of the Congo 
revealed	 an	 IFG	prevalence	of	9.5%	 in	males	 and	9.2%	 in	
females,	respectively,	while	the	prevalence	of	IGT	was	6.4%	
in males and 8.2% in females.[51] Among the Fulbe ethnic 
group	of	Cameroon,	IFG	was	prevalent	in	7.7%	of	males	and	




of 8.2% among the males, while the females had a prevalence 
value of 8.7%.[52] A recent study among newly diagnosed 
hypertensive	 patients	 in	Cameroon	 revealed	 that	 IFG	was	
prevalent at 23.7%.[53] Among a cross-section of adult rural 
dwellers	in	Chad,	IFG	was	prevalent	in	9%	of	the	females	and	
2.77% of the males, giving an overall prevalence of 5.44% 
when both genders were clustered together.[54]
Prediabetes in West Africa
A	 cross‑section	 of	 adults	 aged	 ≥18	 years	 residing	 in	 the	
Borgou	 area	 of	Benin	Republic	 had	 an	 IFG	prevalence	 of	
12.4%	 (WHO	criteria).[55]	Among	adults	 aged	≥20	years	 in	
urban	Ouagadougou,	Burkina	 Faso,	 IFG	was	 prevalent	 at	
5.9%.[56]	In	Abidjan,	urban	Cote	d’	Ivoire,	IFG	was	prevalent	
at 14.5% among a cross-section of children and adolescents 
aged	 between	 2	 and	 19	 years	with	 no	 significant	 gender	
differences.[57]	The	prevalence	of	IFG	and	IGT	among	adult	
patients	 attending	 outpatient	 clinics	 in	Banjul	 urban,	 the	
Gambia,	was	10%	and	32%,	respectively,[58] and hypertension 
emerged	as	the	major	risk	factor	for	IGT.	In	a	community‑based	
prevalence	study	among	adults	aged	≥25	years	in	urban	Accra	
Ghana,	 IFG	 and	 IGT	were	 prevalent	 at	 6.0%	 and	 10.7%,	
respectively, with hypertension found to be significantly 
associated with worsening glycemic states.[59]	In	rural	Ghana,	
a	 community‑based	 study	 revealed	 IGT	 to	 be	 prevalent	 at	
28.7%	among	adults	aged	≥18	years.[60]	In	Guinea	Conakry,	the	
combined	prevalence	of	IFG	in	both	urban	and	rural	areas	was	
13.4%	among	adults	aged	≥35	years.[61] Among a cross-section 
of	Liberian	adults	from	five	randomly	selected	counties	aged	
between	25	and	64	years,	IFG	was	prevalent	at	14.9%	overall,	
though the males and females had prevalence values of 14% 
and 15.7%, respectively.[62]
A	pioneer	study	of	the	prevalence	of	IGT,	in	a	Nigerian	city	
done in 1998, revealed a prevalence rate of 2.2%, while that of 
diabetes, it was 0.8%, and the study showed no sex differences 
in the prevalence rates.[63]
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Among the hypertensive patients attending a tertiary 
health-care facility in Southeast Nigeria, the prevalence of 
prediabetes	was	25%.	Of	these,	14%	had	IFG,	5%	had	IGT,	
while	6%	had	both	IFG	and	IGT.[65]
In	 a	 recent	 study	 in	 rural	 Southeast	Nigeria,	 IFG	and	 IGT	
were prevalent at 9.2% and 15.8%, respectively, in adults 
aged	≥18	years	using	the	WHO	criteria,[66]	with	no	significant	
gender bias, and hypertension emerged as the strongest 
predictor of prediabetes. In this same community, when the 
ADA	criteria	applied,	the	prevalence	figures	for	IFG	rose	to	
27.2%.[67] Among a cross-section of rural Fulani individuals 
in	Northern	Nigeria,	IFG	and	IGT	were	prevalent	at	6.9%	and	
8.0%, respectively.[68] Among urban-dwelling secondary school 
students	 in	 Port	Harcourt,	 Southern	Nigeria,	whose	mean	
age	was	15	±	2	years,	the	IFG	was	prevalent	at	4%	using	the	
WHO	criteria.[69]	In	a	rural	Senegalese	community,	 the	IFG	
was prevalent at 6.6% among a cross-section of adults with 
no	significant	gender	disparity.[70]
Prediabetes in Southern Africa
In	Buffalo	City	Metropolitan	Municipality	in	South	Africa,	IFG	
was prevalent at 14% among the adult residents.[71] Among a 
cross‑section	of	a	rural	Zulu	community,	IFG	was	prevalent	
at	4.0%	in	the	males	and	0.8%	in	the	females,	while	IGT	was	
almost equally prevalent in both genders at 4.6% in the males 
and 4.7% in the females.[72]




was prevalent at 14.4%, while the combined prevalence of 
IFG	 and	 IGT	was	 29.1%.[74] In Cape Town, South Africa, 
6.0%	and	5.9%	of	males	and	females,	respectively,	had	IGT.[75] 
Among newly presenting hypertensive patients in South Africa, 
IGT	was	found	to	be	highly	prevalent	at	30.0%.[76] In urban 
Botswana,	among	adults	attending	outpatient	clinics,	IFG	was	




Within the past few decades, several landmark studies were 
initiated	 to	 determine	 the	 benefit	 or	 otherwise	 of	 various	
strategies – use of some classes of drugs or intensive lifestyle 
intervention – and aimed at preventing or delaying the onset of 
T2DM in people with prediabetes, with remarkable results.[31-37] 
Findings from these studies have revealed that progression from 
prediabetes to T2DM is not ineluctable. Indeed, prediabetes 
can be halted and even reversed, as some individuals with 
IGT	were	observed	to	revert	to	NGT	with	intensive	lifestyle	
changes targeting modest weight loss, increased physical 
activity,	and	dietary	pattern	changes.	However,	a	more	cursory	
look	revealed	that	although	drugs	contributed	significantly	to	
decrease progression to T2DM, their effect was disappointingly 
short lived, and in most cases, not lasting up to 3 months 
after cessation of the drugs.[18] On the other hand, intensive 
lifestyle intervention, a cost-effective and eminently harmless 
process, was shown to have a profound and (perhaps more 
importantly)	sustained	beneficial	effect,	even	up	to	a	decade	
or more, post intervention[18,79] – a phenomenon now widely 
referred to as the “legacy effect.”[80] Studies on the progression 
from prediabetes to diabetes in Sub-Saharan Africa as well as 
advocacy and campaigns for the adoption of healthy lifestyles 
by the population are needed to halt the increase in diabetes 
prevalence in this region.
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